# Novacea

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/novacea

- Industry: Healthcare Specialists
- Headquarters: San Francisco, US
- Website: www.novacea.com
- Total disclosed funding: $60M
- Latest round: Series C (Jan 16, 2006)
- Investors on record: 6

## About

Novacea, Inc. is a US-based biopharmaceutical company focused on developing innovative treatments for cancer. It aims to enhance patient outcomes through advanced drug development and research initiatives.Novacea, Inc. specializes in biopharmaceuticals targeting cancer therapies. The company was founded in San Francisco, US. In May 2006, Novacea went public, raising USD 40.63 mn from its IPO by selling 6.25 million shares at USD 6.5 each. In January 2009, Novacea was acquired by Transcept Pharmaceuticals, Inc.Novacea, Inc. focuses on developing drug therapies for cancer, employing cutting-edge research and clinical trials to advance its product offerings. The company’s portfolio includes investigational drugs aimed at improving treatment outcomes for cancer patients.In the most recent fiscal year of 2022, Novacea reported a revenue of USD 160.27 mn, alongside an EBITDA of USD -45.72 mn, highlighting the company's operational financials amid its ongoing development efforts.Following its IPO in May 2006, Novacea plans to leverage its recent funding to enhance R&D capabilities and expand its pipeline of cancer therapies. The company is targeting the launch of new products aimed at specific cancer types by 2025, while also exploring expansion into international markets, particularly in Europe and Asia, to broaden its reach and impact.

## Funding rounds

- Series C, Jan 16, 2006, $25M — Apax Partners, Domain Associates, New Enterprise Associates, Sofinnova Investments, Versant Ventures, ProQuest Investments
- Series C, Jan 8, 2004, $35M — Apax Partners, Domain Associates, New Enterprise Associates, Sofinnova Investments, Versant Ventures, ProQuest Investments

## Investors

- Apax Partners (https://capitalatlas.ai/funds/apax-partners) — Series C
- Domain Associates (https://capitalatlas.ai/funds/domain-associates) — Series C
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series C
- Sofinnova Investments (https://capitalatlas.ai/funds/sofinnova-investments) — Series C
- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series C
- ProQuest Investments (https://capitalatlas.ai/funds/proquest-investments) — Series C